New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Rhea-AI Summary

Indivior (NASDAQ: INDV) reported a retrospective real-world study published March 11, 2026 linking 12-month adherence to SUBLOCADE (monthly injectable buprenorphine) with substantially lower healthcare use and costs in commercially insured patients with opioid use disorder.

Key result: SUBLOCADE-adherent patients had $15,017 (42%) lower annual non-MOUD medical costs versus patients adherent to other MOUD ($35,761 vs $50,778), plus the lowest inpatient, ED, and detox utilization. Study limitations include observational claims data and COVID-19 overlap.

Positive

• $15,017 (42%) lower annual non-MOUD medical costs for SUBLOCADE-adherent patients versus other MOUD
• SUBLOCADE-adherent patients had the lowest inpatient admissions, emergency department visits, and detox utilization
• Consistent monthly injectable use linked to lower overall healthcare expenditures across treatment groups

Negative

• Study is retrospective and observational, limiting causal inference from associations
• Analysis relies on administrative claims data subject to coding inaccuracies and unmeasured confounding
• Portions of the study overlapped with the COVID-19 pandemic, which may have affected utilization patterns
• Overall adherence to MOUD remained low across groups, indicating persistent treatment continuity challenges

News Market Reaction – INDV

-1.53%

9 alerts

-1.53% News Effect

-$68M Valuation Impact

$4.41B Market Cap

0.3x Rel. Volume

On the day this news was published, INDV declined 1.53%, reflecting a mild negative market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $68M from the company's valuation, bringing the market cap to $4.41B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cost reduction vs MOUD: $15,017 lower annual non-MOUD medical costs per patient Non-MOUD cost difference: 42% lower adjusted non-MOUD medical costs SUBLOCADE non-MOUD costs: $35,761 annual non-MOUD medical costs +2 more

5 metrics

Cost reduction vs MOUD $15,017 lower annual non-MOUD medical costs per patient SUBLOCADE-adherent vs other MOUD

Non-MOUD cost difference 42% lower adjusted non-MOUD medical costs SUBLOCADE-adherent vs other MOUD

SUBLOCADE non-MOUD costs $35,761 annual non-MOUD medical costs Patients adherent to SUBLOCADE

Other MOUD non-MOUD costs $50,778 annual non-MOUD medical costs Patients adherent to other MOUD

Follow-up duration 12 months Study follow-up for SUBLOCADE adherence and outcomes

Market Reality Check

Price: $30.86 Vol: Volume 4,362,125 is 2.07x...

high vol

$30.86 Last Close

Volume Volume 4,362,125 is 2.07x the 20-day average of 2,105,580, indicating elevated interest ahead of this study news. high

Technical Price at 33.34 is trading above the 200-day MA of 26, reflecting a pre-existing uptrend into this announcement.

Peers on Argus

INDV was up 2.27% with high volume, while close peers showed mixed, mostly modes...

1 Down

INDV was up 2.27% with high volume, while close peers showed mixed, mostly modest moves (e.g., HCM +0.8%, AMRX +1.06%, SUPN -1.14%). Momentum scanner activity was limited to one down-moving peer (ALVO), supporting a stock-specific reaction to the SUBLOCADE outcomes rather than a broad sector rotation.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings results	Positive	+0.2%	Record 2025 SUBLOCADE revenue and strong earnings metrics with 2026 guidance.
Feb 24	Investor conferences	Neutral	+0.4%	Participation in March healthcare conferences and a public fireside chat webcast.
Jan 28	Earnings date set	Neutral	+0.6%	Announcement of Q4 and full‑year 2025 results date and webcast details.
Jan 26	Redomiciliation	Positive	+1.9%	Completion of redomiciliation to U.S. with continued Nasdaq listing under INDV.
Jan 08	Guidance & update	Positive	-1.1%	2026 guidance, restructuring savings, index inclusion and DOJ matter resolution.

Pattern Detected

Recent news has mostly seen modest positive price alignment, with one divergence on a guidance/business update.

Recent Company History

Over the last few months, INDV’s narrative centered on SUBLOCADE growth and corporate repositioning. Earnings on Feb 26, 2026 highlighted record SUBLOCADE revenue and solid profitability with a slightly positive price reaction. Guidance and a broader business update on Jan 8, 2026 saw a small negative move despite constructive metrics. Redomiciliation to the U.S. on Jan 26, 2026 and index inclusion/strategic steps have generally aligned with modest gains. Today’s clinical-utility and cost-effectiveness data further reinforce the SUBLOCADE-focused story.

Market Pulse Summary

This announcement highlights real-world evidence that monthly injectable SUBLOCADE adherence over 12...

Analysis

This announcement highlights real-world evidence that monthly injectable SUBLOCADE adherence over 12 months is associated with lower inpatient, emergency, and detox utilization and $15,017 lower annual non-MOUD medical costs per patient, a 42% reduction versus other MOUD. It reinforces Indivior’s strategy emphasizing long-acting treatments and follows prior disclosures of strong SUBLOCADE revenue growth. Investors may watch for how such health-economic data influences payer adoption, treatment guidelines, and future updates in regulatory filings.

Key Terms

extended-release buprenorphine, opioid use disorder, real-world evidence, retrospective observational study, +2 more

6 terms

extended-release buprenorphine medical

"SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated"

Extended-release buprenorphine is a long-acting form of a medication used to treat opioid dependence or chronic pain that releases a measured dose slowly over days or months after a single injection or implant. For investors, it matters because longer dosing can improve patient adherence and lower treatment costs, which can translate to steadier sales, regulatory scrutiny over safety and reimbursement decisions, and different competitive dynamics than short-acting products.

opioid use disorder medical

"insured patients with opioid use disorder (OUD). These outcomes were more"

Opioid use disorder is a medical condition where a person repeatedly seeks and uses opioid drugs despite harmful physical, social or mental effects, often involving strong cravings and withdrawal symptoms when stopping. It matters to investors because its prevalence, availability of effective treatments, regulatory responses, and legal or insurance costs can shift demand, revenue and risk across drug makers, treatment providers and insurers—like a widespread problem that reshapes an entire market.

real-world evidence medical

"findings from a new real-world evidence, retrospective observational study"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

retrospective observational study medical

"new real-world evidence, retrospective observational study published in"

A retrospective observational study looks back at existing records or data to examine patterns, outcomes or associations, like reviewing past receipts to see what purchases led to returns. It does not assign treatments or control groups, so it can suggest links but cannot prove cause, making its findings useful for early signals or hypothesis generation but less definitive for regulatory approval or investment decisions that require stronger evidence.

administrative claims data technical

"design and reliance on administrative claims data, which may be subject"

Administrative claims data are digital records created when healthcare providers bill insurers for services—think of them as detailed receipts that list diagnoses, procedures, dates of care and amounts charged or paid. Investors use these records as a large, real-world window into healthcare use, treatment patterns, and spending trends, which helps estimate market demand, adoption of therapies, pricing pressure and revenue potential for healthcare products and services.

MOUD medical

"other medications for OUD (MOUD) and to those who were nonadherent"

MOUD stands for medications for opioid use disorder — prescription drugs such as methadone, buprenorphine and naltrexone that reduce cravings and withdrawal for people addicted to opioids. For investors, MOUD represents a regulated medical product category whose approval, insurance coverage and uptake directly affect revenue potential for drug makers and treatment providers, much like how demand and regulation shape markets for any essential, life-supporting product.

AI-generated analysis. Not financial advice.

• Patients adherent to SUBLOCADE^® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD
• Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups

RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE^® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder (OUD). These outcomes were more favorable compared to both patients adherent to other medications for OUD (MOUD) and to those who were nonadherent to MOUD.

These findings add to growing evidence that long-acting injectable buprenorphine treatment supports sustained engagement in care and reduces costly acute healthcare use.

To evaluate the relationship between treatment adherence, medication type, healthcare utilization, and costs, patients were grouped based on adherence level and primary MOUD received during follow-up including: those adherent to SUBLOCADE, those not adherent to SUBLOCADE but adherent to other MOUD (e.g., transmucosal buprenorphine), and those who were not adherent to any MOUD.

Patients who were adherent to SUBLOCADE across the 12-month follow-up experienced the lowest rates of inpatient admissions, emergency department visits, and detoxification services across all other groups.

Key findings:

• $15,017 (42%) lower annual non-MOUD medical costs per patient for SUBLOCADE-adherent patients vs other MOUD ($35,761 vs. $50,778).
• Lower adjusted costs observed among MOUD nonadherent patients likely reflect disengagement from routine outpatient care, and greater reliance on acute services.

“These data highlight the potential of long-acting injectable buprenorphine treatment to improve care continuity for people living with OUD and reduce the need for acute, high-cost healthcare services,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior.

Across treatment groups, consistent use of a monthly injectable buprenorphine was associated with lower overall healthcare expenditures compared with adherence to other MOUD. Consistent with other research, this study found that adherence to MOUD remains low overall, underscoring the broader challenges of treatment continuity in OUD care.

"These findings reinforce the importance of evaluating OUD treatment based on total healthcare cost,” said Patrick Barry, Chief Commercial Officer at Indivior. “Sustained engagement with long-acting therapy can reduce costly acute care use, generating meaningful system-wide savings while supporting treatment continuity for patients."

Study limitations include the retrospective observational design and reliance on administrative claims data, which may be subject to coding inaccuracies and unmeasured confounding. Portions of the study period overlapped with the COVID-19 pandemic, where disruptions in care may have influenced healthcare utilization patterns. At the time the study was conducted, SUBLOCADE was the only extended-release buprenorphine product available in the U.S. market.

The study is available online: Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder

About SUBLOCADE®

SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII

INDICATION AND HIGHLIGHTED SAFETY INFORMATION

INDICATION

SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.

HIGHLIGHTED SAFETY INFORMATION

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY

• Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
• Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.

CONTRAINDICATIONS

Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE.

WARNINGS AND PRECAUTIONS

Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.

Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.

Risk of Serious Injection Site Reactions: Likelihood may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema, and pruritus with some involving abscess, ulceration, and necrosis.

Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.

Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.

Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.

Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment.

Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE.

Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.

ADVERSE REACTIONS

Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain.

For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com. 

About Opioid Use Disorder (OUD) 
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions.

About Indivior 
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior. 

For Further Information 
Investors: 
Jason Thompson 
Indivior Pharmaceuticals 
Tel: 804-402-7123 
E-mail: jason.thompson@indivior.com 

Media: 
Cassie France-Kelly 
Indivior Pharmaceuticals 
Tel: 804-594-0836 
E-mail: Indiviormediacontacts@indivior.com

FAQ

What did Indivior report about SUBLOCADE adherence and healthcare costs for INDV on March 11, 2026?

Adherence to SUBLOCADE for 12 months was linked to significantly lower costs and utilization. According to the company, SUBLOCADE-adherent patients had $15,017 (42%) lower annual non-MOUD medical costs versus patients adherent to other MOUD, with reduced inpatient and ED use.

How much lower were annual non-MOUD medical costs for SUBLOCADE-adherent patients (INDV)?

Annual non-MOUD medical costs were $15,017 lower for SUBLOCADE-adherent patients. According to the company, that equals a 42% reduction versus other MOUD adherent patients ($35,761 vs $50,778), measured across a 12-month follow-up.

What healthcare utilizations decreased among patients adherent to SUBLOCADE in the INDV study?

SUBLOCADE adherence was associated with the lowest inpatient, emergency department, and detoxification utilization. According to the company, adherent patients experienced fewer admissions, ED visits, and detox services compared with other MOUD and nonadherent groups.

What limitations did Indivior note about the SUBLOCADE adherence study (INDV)?

The study was retrospective and used administrative claims, limiting causal conclusions. According to the company, results may be affected by coding inaccuracies, unmeasured confounding, and overlapping COVID-19 care disruptions during the study period.

Does the INDV study show SUBLOCADE causes lower costs or just an association?

The study shows an association, not definitive causation. According to the company, the retrospective observational design and claims-based data limit causal inference, so findings indicate correlation between SUBLOCADE adherence and lower healthcare use and costs.